{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"146","upperLimit":"281","value":"214.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"144"}],"units":"Participants"}],"description":"Time to disease progression (TTP) was based on the European Group for Blood and Marrow Transplantation (EBMT) myeloma response determination criteria developed by Bladé (Bladé, 1998). TTP is a Kaplan Meier estimate of the time from randomization to the first documentation of progressive disease.\n\nProgressive disease based on increasing monoclonal paraprotein levels require a confirmatory value one week apart. Disease progression can also be based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.","dispersionType":"95% Confidence Interval","groups":[{"description":"Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), dexamethasone was to be reduced to 40 mg QD for Days 1-4 of each 28 day-cycle.","id":"OG000","title":"Lenalidomide Plus Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Full analysis dataset","reportingStatus":"POSTED","timeFrame":"up to 827 days","title":"Kaplan Meier Estimate for Time to Disease Progression","type":"PRIMARY","unitOfMeasure":"days"}